LPCN vs. MNOV, EDIT, ME, ABOS, ORMP, ATRA, IMUX, ACOG, XFOR, and CLLS
Should you be buying Lipocine stock or one of its competitors? The main competitors of Lipocine include MediciNova (MNOV), Editas Medicine (EDIT), 23andMe (ME), Acumen Pharmaceuticals (ABOS), Oramed Pharmaceuticals (ORMP), Atara Biotherapeutics (ATRA), Immunic (IMUX), Alpha Cognition (ACOG), X4 Pharmaceuticals (XFOR), and Cellectis (CLLS). These companies are all part of the "pharmaceutical products" industry.
Lipocine vs.
MediciNova (NASDAQ:MNOV) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, community ranking, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.
MediciNova has higher revenue and earnings than Lipocine. MediciNova is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.
MediciNova's return on equity of -17.55% beat Lipocine's return on equity.
MediciNova has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, Lipocine has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500.
9.9% of MediciNova shares are owned by institutional investors. Comparatively, 9.1% of Lipocine shares are owned by institutional investors. 14.9% of MediciNova shares are owned by company insiders. Comparatively, 6.1% of Lipocine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
MediciNova presently has a consensus target price of $9.00, suggesting a potential upside of 391.80%. Lipocine has a consensus target price of $10.00, suggesting a potential upside of 115.47%. Given MediciNova's higher possible upside, research analysts clearly believe MediciNova is more favorable than Lipocine.
Lipocine received 137 more outperform votes than MediciNova when rated by MarketBeat users. Likewise, 68.71% of users gave Lipocine an outperform vote while only 48.39% of users gave MediciNova an outperform vote.
In the previous week, MediciNova and MediciNova both had 2 articles in the media. Lipocine's average media sentiment score of 0.50 beat MediciNova's score of 0.00 indicating that Lipocine is being referred to more favorably in the news media.
Summary
MediciNova beats Lipocine on 9 of the 14 factors compared between the two stocks.
Get Lipocine News Delivered to You Automatically
Sign up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lipocine Competitors List
Related Companies and Tools
This page (NASDAQ:LPCN) was last updated on 1/21/2025 by MarketBeat.com Staff
